Vetr upgraded shares of Gilead Sciences (NASDAQ:GILD) from a buy rating to a strong-buy rating in a research note issued to investors on Monday morning. They currently have $91.25 price target on the biopharmaceutical company’s stock.
Several other brokerages have also recently commented on GILD. JPMorgan Chase & Co. set a $85.00 target price on shares of Gilead Sciences and gave the company a buy rating in a research report on Wednesday, October 25th. BMO Capital Markets reiterated a hold rating and set a $82.00 target price on shares of Gilead Sciences in a research report on Friday, October 20th. Citigroup upgraded shares of Gilead Sciences from a neutral rating to a buy rating and dropped their target price for the company from $88.80 to $76.00 in a research report on Tuesday, January 30th. Zacks Investment Research cut shares of Gilead Sciences from a hold rating to a sell rating in a research report on Wednesday, October 18th. Finally, William Blair reiterated a buy rating on shares of Gilead Sciences in a research report on Thursday, October 19th. One research analyst has rated the stock with a sell rating, twelve have issued a hold rating, seventeen have assigned a buy rating and two have given a strong buy rating to the company’s stock. Gilead Sciences currently has a consensus rating of Buy and a consensus price target of $85.58.
Shares of Gilead Sciences (NASDAQ GILD) opened at $82.76 on Monday. The company has a market cap of $104,997.90, a price-to-earnings ratio of 9.41, a price-to-earnings-growth ratio of -1.77 and a beta of 1.22. Gilead Sciences has a 1 year low of $63.76 and a 1 year high of $89.54. The company has a current ratio of 3.68, a quick ratio of 3.56 and a debt-to-equity ratio of 1.10.
The company also recently announced a quarterly dividend, which will be paid on Thursday, March 29th. Shareholders of record on Friday, March 16th will be issued a dividend of $0.57 per share. This represents a $2.28 dividend on an annualized basis and a yield of 2.75%. The ex-dividend date is Thursday, March 15th. This is a boost from Gilead Sciences’s previous quarterly dividend of $0.52. Gilead Sciences’s dividend payout ratio is 59.77%.
In other Gilead Sciences news, Chairman John C. Martin sold 50,000 shares of the stock in a transaction dated Thursday, February 1st. The stock was sold at an average price of $83.56, for a total transaction of $4,178,000.00. Following the completion of the transaction, the chairman now owns 3,046,766 shares in the company, valued at approximately $254,587,766.96. The transaction was disclosed in a filing with the SEC, which is available through the SEC website. Also, EVP Gregg H. Alton sold 25,000 shares of the stock in a transaction dated Thursday, February 1st. The stock was sold at an average price of $83.51, for a total value of $2,087,750.00. Following the transaction, the executive vice president now owns 62,738 shares of the company’s stock, valued at approximately $5,239,250.38. The disclosure for this sale can be found here. In the last quarter, insiders have sold 578,333 shares of company stock valued at $44,100,508. Corporate insiders own 1.30% of the company’s stock.
A number of hedge funds have recently added to or reduced their stakes in the business. Welch Investments LLC acquired a new position in shares of Gilead Sciences during the 3rd quarter worth about $108,000. Wealthcare Advisory Partners LLC acquired a new position in shares of Gilead Sciences during the 3rd quarter worth about $133,000. Horan Capital Advisors LLC. acquired a new position in shares of Gilead Sciences during the 3rd quarter worth about $144,000. Migdal Insurance & Financial Holdings Ltd. acquired a new position in shares of Gilead Sciences during the 2nd quarter worth about $147,000. Finally, Hanson & Doremus Investment Management boosted its stake in shares of Gilead Sciences by 806.5% during the 3rd quarter. Hanson & Doremus Investment Management now owns 1,813 shares of the biopharmaceutical company’s stock worth $147,000 after buying an additional 1,613 shares during the last quarter. Hedge funds and other institutional investors own 75.84% of the company’s stock.
COPYRIGHT VIOLATION NOTICE: This news story was originally reported by Sports Perspectives and is the sole property of of Sports Perspectives. If you are accessing this news story on another domain, it was stolen and republished in violation of US and international trademark & copyright law. The original version of this news story can be accessed at https://sportsperspectives.com/2018/02/08/gilead-sciences-gild-upgraded-at-vetr.html.
About Gilead Sciences
Gilead Sciences, Inc is a research-based biopharmaceutical company that discovers, develops and commercializes medicines in areas of unmet medical need. The Company’s portfolio of products and pipeline of investigational drugs includes treatments for Human Immunodeficiency Virus/Acquired Immune Deficiency Syndrome (HIV/AIDS), liver diseases, cancer, inflammatory and respiratory diseases and cardiovascular conditions.
To view Vetr’s full report, visit Vetr’s official website.
Receive News & Ratings for Gilead Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Gilead Sciences and related companies with MarketBeat.com's FREE daily email newsletter.